Copper reduces Aβoligomeric species and ameliorates neuromuscular synaptic defects in a C. Elegans model of inclusion body myositis

Journal of Neuroscience

Volumn 31, Issue 28, 2011, Pages 10149-10158

  Rebolledo, Daniela L ^a   Aldunate, Rebeca ^a,b   Kohn, Rebecca ^c   Neira, Iván ^a,d   Minniti, Alicia N ^a   Inestrosa, Nibaldo C ^a  

^a Centro de Envejecimiento y Regeneración ^*  (Chile)

^b UNIVERSIDAD SANTO TOMÁS   (Chile)

^c Ursinus College   (Chile)

^d UNIVERSIDAD DE ANTOFAGASTA   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINERGIC RECEPTOR; COPPER;

ARTICLE; BIOCHEMISTRY; CAENORHABDITIS ELEGANS; HISTOLOGY; INCLUSION BODY MYOSITIS; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYNAPTIC TRANSMISSION;

AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; COPPER; DISEASE MODELS, ANIMAL; MYOSITIS, INCLUSION BODY; NEUROMUSCULAR JUNCTION; PLAQUE, AMYLOID;

EID: 79960434279     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0336-11.2011     Document Type: Article

References (72)

1. Askanas V, Engel WK (2006) Inclusion-body myositis: a myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition. Neurology 66:S39-S48.
2. Askanas V, Engel WK (2007) Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19:550-559.
3. Askanas V, Engel WK, Alvarez RB (1998) Fourteen newly recognized proteins at the human neuromuscular junctions-and their nonjunctional accumulation in inclusion-body myositis. Ann N Y Acad Sci 841:28-56.
4. Ballivet M, Alliod C, Bertrand S, Bertrand D (1996) Nicotinic acetylcholine receptors in the nematode Caenorhabditis elegans. J Mol Biol 258: 261-269.
5. Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR (2006) Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 66:S123-S124.
6. Bitan G, Fradinger EA, Spring SM, Teplow DB (2005) Neurotoxic protein oligomers-what you see is not always what you get. Amyloid 12:88-95.
7. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77:71-94.
8. Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 61:39-61.
9. Bush AI, Pettingell WH Jr, Paradis MD, Tanzi RE (1994a) Modulation of Aβ adhesiveness and secretase site cleavage by zinc. J Biol Chem 269:12152-12158.
10. Bush AI, Pettingell WH, Multhaup G, Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994b) Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 265:1464-1467.
11. Calay D, Rousseau A, Mattart L, Nuyens V, Delporte C, Van Antwerpen P, Moguilevsky N, Arnould T, Boudjeltia KZ, Raes M (2010) Copper and myeloperoxidase-modified LDLs activate Nrf2 through different pathways of ROS production in macrophages. Antioxid Redox Signal 13:1491-1502.
12. Cerpa W, Varela-Nallar L, Reyes AE, Minniti AN, Inestrosa NC (2005) Is there a role for copper in neurodegenerative diseases? Mol Aspects Med 26:405-420.
13. Cerpa W, Dinamarca MC, Inestrosa NC (2008) Structure-function implications in Alzheimer's disease: effect of Aβ oligomers at central synapses. Curr Alzheimer Res 5:233-243.
14. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
15. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8:79-84.
16. Culetto E, Sattelle DB (2000) A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum Mol Genet 9:869-877.
17. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323-327.
18. D'Andrea MR, Nagele RG (2006) Targeting the β7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des 12:677-684.
19. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601.
20. Dineley KT, Bell KA, Bui D, Sweatt JD (2002) β-Amyloid peptide activates β7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277:25056-25061.
21. Dominguez del Toro E, Juiz JM, Peng X, Lindstrom J, Criado M (1994) Immunocytochemical localization of the β7 subunit of the nicotinic acetylcholine receptor in the rat central nervous system. J Comp Neurol 349:325-342.
22. Dosanjh LE, Brown MK, Rao G, Link CD, Luo Y (2010) Behavioral phenotyping of a transgenic Caenorhabditis elegans expressing neuronal amyloid-β. J Alzheimers Dis 19:681-690.
23. Dostal V, Roberts CM, Link CD (2010) Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of β-amyloid peptide toxicity. Genetics 186:857-866.
24. Drago J, McColl CD, Horne MK, Finkelstein DI, Ross SA (2003) Neuronal nicotinic receptors: insights gained from gene knockout and knockin mutant mice. Cell Mol Life Sci 60:1267-1280.
25. Fay DS, Fluet A, Johnson CJ, Link CD (1998) In vivo aggregation of β-amyloid peptide variants. J Neurochem 71:1616-1625.
26. Fleming JT, Squire MD, Barnes TM, Tornoe C, Matsuda K, Ahnn J, Fire A, Sulston JE, Barnard EA, Sattelle DB, Lewis JA (1997) Caenorhabditis elegans levamisole resistance genes lev-1, unc-29, and unc-38 encode functional nicotinic acetylcholine receptor subunits. J Neurosci 17: 5843-5857.
27. Francis MM, Evans SP, Jensen M, Madsen DM, Mancuso J, Norman KR, Maricq AV (2005) The Ror receptor tyrosine kinase CAM-1 is required for ACR-16-mediated synaptic transmission at the C. elegans neuromuscular junction. Neuron 46:581-594.
28. Gally C, Eimer S, Richmond JE, Bessereau JL (2004) A transmembrane protein required for acetylcholine receptor clustering in Caenorhabditis elegans. Nature 431:578-582.
29. Gottschalk A, Almedom RB, Schedletzky T, Anderson SD, Yates JR 3rd, Schafer WR (2005) Identification and characterization of novel nicotinic receptor-associated proteins in Caenorhabditis elegans. EMBO J 24:2566-2578.
30. Kahn NW, Rea SL, Moyle S, Kell A, Johnson TE (2008) Proteasomal dysfunction activates the transcription factor SKN-1 and produces a selective oxidative-stress response in Caenorhabditis elegans. Biochem J 409:205-213.
31. Kanninen K, Malm TM, Jyrkkanen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H, Yamamoto M, Yla-Herttuala S, Levonen AL, Koistinaho J (2008) Nuclear factor erythroid 2-related factor 2 protects against β-amyloid. Mol Cell Neurosci 39:302-313.
32. Kanninen K, Heikkinen R, Malm T, Rolova T, Kuhmonen S, Leinonen H, Yla-Herttuala S, Tanila H, Levonen AL, Koistinaho M, Koistinaho J (2009) Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106:16505-16510.
33. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489.
34. Kell A, Ventura N, Kahn N, Johnson TE (2007) Activation of SKN-1 by novel kinases in Caenorhabditis elegans. Free Radic Biol Med 43:1560-1566.
35. Kessler H, Pajonk FG, Supprian T, Falkai P, Multhaup G, Bayer TA (2005) [The role of copper in the pathophysiology of Alzheimer's disease]. Nervenarzt 76:581-585.
36. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796-807.
37. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440:352-357.
38. Lewis JA, Fleming JT (1995) Basic culture methods. Methods Cell Biol 48:3-29.
39. Link CD (1995) Expression of humanβ-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A 92:9368-9372.
40. Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, Sahagan BG (2003) Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol Aging 24:397-413.
41. Liu Q, Kawai H, Berg DK (2001) β-Amyloid peptide blocks the response of β7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A 98:4734-4739.
42. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158:47-52.
43. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, Laferla FM, Jin LW (2008) Congo red and thioflavin-T analogs detect Aβ oligomers. J Neurochem 104:457-468.
44. Mahoney TR, Luo S, Nonet ML (2006) Analysis of synaptic transmission in Caenorhabditis elegans using an aldicarb-sensitivity assay. Nat Protoc 1:1772-1777.
45. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, Morris JC (2001a) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56:127-129.
46. Masliah E, Alford M, Galasko D, Salmon D, Hansen LA, Good PF, Perl DP, Thal L (2001b) Cholinergic deficits in the brains of patients with parkinsonism-dementia complex of Guam. Neuroreport 12:3901-3903.
47. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4:2757-2763.
48. McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny RA, Bush AI (2009) The Caenorhabditis elegans Aβ1-42 model of Alzheimer disease predominantly expresses Aβ3-42. J Biol Chem 284:22697-22702.
49. McFerrin J, Engel WK, Askanas V (1998) Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion-body myopathies. Neuroreport 9:3201-3205.
50. Miller KG, Alfonso A, Nguyen M, Crowell JA, Johnson CD, Rand JB (1996) A genetic selection for Caenorhabditis elegans synaptic transmission mutants. Proc Natl Acad Sci U S A 93:12593-12598.
51. Minniti AN, Rebolledo DL, Grez PM, Fadic R, Aldunate R, Volitakis I, Cherny RA, Opazo C, Masters C, Bush AI, Inestrosa NC (2009) Intracellular amyloid formation in muscle cells of Aβ-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. Mol Neurodegener 4:2.
52. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
53. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY (2002) Intracellular accumulation of β-amyloid(1-42) in neurons is facilitated by the β7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110:199-211.
54. Nogalska A, D'Agostino C, Engel WK, Klein WL, Askanas V (2010) Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 120:661-666.
55. Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairbairn A, Blessed G (1987) Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 50:806-809.
56. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH (1995) Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64:385-395.
57. Quirion R, Martel JC, Robitaille Y, Etienne P, Wood P, Nair NP, Gauthier S (1986) Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci 13:503-510.
58. Rebolledo DL, Minniti AN, Grez PM, Fadic R, Kohn R, Inestrosa NC (2008) Inclusion body myositis: a view from the Caenorhabditis elegans muscle. Mol Neurobiol 38:178-198.
59. Richmond JE, Jorgensen EM (1999) One GABA and two acetylcholine receptors function at the C. elegans neuromuscular junction. Nat Neurosci 2:791-797.
60. Schmidt ML, Schuck T, Sheridan S, Kung MP, Kung H, Zhuang ZP, Bergeron C, Lamarche JS, Skovronsky D, Giasson BI, Lee VM, Trojanowski JQ (2001) The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4- hydroxy)styrylbenzene (BSB), labels diverse β-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol 159:937-943.
61. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298: 789-791.
62. Selkoe DJ (2007) Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. Nutr Rev 65:S239-243.
63. Simmons SO, Fan C-Y, Yeoman K, Wakefield J, Ramabhadran R (2011) NRF2 oxidative stress induced by heavy metals is cell type dependent. Curr Chem Genomics 5:1-12.
64. Strausak D, Mercer JF, Dieter HH, Stremmel W, Multhaup G (2001) Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull 55:175-185.
65. Toledo EM, Inestrosa NC (2009) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15:272-285, 228.
66. Touroutine D, Fox RM, Von Stetina SE, Burdina A, Miller DM 3rd, Richmond JE (2005) Acr-16 encodes an essential subunit of the levamisoleresistant nicotinic receptor at the Caenorhabditis elegans neuromuscular junction. J Biol Chem 280:27013-27021.
67. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000b) β-Amyloid(1-42) binds to β7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275:5626-5632.
68. Wang HY, Lee DH, Davis CB, Shank RP (2000a) Amyloid peptide Aβ(1- 42) binds selectively and with picomolar affinity to β7 nicotinic acetylcholine receptors. J Neurochem 75:1155-1161.
69. Wang XJ, Hayes JD, Higgins LG, Wolf CR, Dinkova-Kostova AT (2010) Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones. Chem Biol 17:75-85.
70. Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, Steur EN, Maelicke A, Albuquerque EX, Schroder H (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11:2551-2565.
71. Wruck CJ, Gotz ME, Herdegen T, Varoga D, Brandenburg LO, Pufe T (2008) Kavalactones protect neural cells against amyloid-β peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol Pharmacol 73:1785-1795.
72. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y (2006) Amyloid-β-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102-13113.